ASH News Daily 2012 - Sunday, December 9, 2012 - (Page A-1)

ASH NEWS DAILY 54th Annual Meeting of the American Society of Hematology ® Read this issue online at www.hematology.org/ashnewsdaily2012_sunday SCHEDULE 7:00 – 9:00 a.m. Hematology Course Directors’ Workshop Grand Ballroom A, North Tower Omni Hotel at CNN Center 9:30 – 11:00 a.m. ASH/ASCO Joint Symposium B405-B407, Level 4, Building B 11:15 a.m. – 12:15 p.m. How I Treat: Bringing Science to Clinical Dilemmas (ticketed sessions) Various locations at Omni Hotel at CNN Center 11:15 a.m. – 12:15 p.m. Scientific Forums Various locations at Omni Hotel at CNN Center 12:15 – 1:15 p.m. ASH/EHA Policy Forum Speakers: Douglas Sipp and Alan Trounson, PhD Hall B5, Level 1, Building B 1:15 – 1:45 p.m. Announcement of Awards: Mentor Awards Outstanding Service Award Public Service Award Wallace H. Coulter Award for Lifetime Achievement in Hematology Hall B5, Level 1, Building B 2:00 – 4:00 p.m. Plenary Scientific Session Hall B5, Level 1, Building B 6:15 – 7:15 p.m. Blood and Beyond: Searching the Scientific Literature Online B403, Level 4, Building B 6:30 – 8:00 p.m. The HVO Volunteer Experience: Sharing Your Hematology Expertise Globally A402, Level 4, Building A IN THIS SECTION Lymphocytic Leukemia A-2 GVHD A-14 Anticoagulants Hox Genes A-18 So, You Want to Become an Adult? BY MATTHEW HSIEH, MD S ickle cell disease (SCD) is an inherited disorder of hemoglobin and is manifested by a host of chronic and acute complications with vaso-occlusive pain as the most familiar syndrome. With improved supportive care over the last three decades, most children affected by SCD now live into adulthood. Transitioning to an adult should be a good thing, right? Well, there are some caveats. Marwah W. Farooqui, DO, (abstract 1017) studied a retrospective cohort of children and young adults (up to 30 years old) in the Chicago area and found that as the age increases, so does the proportion of individuals with proteinuria, an early marker for kidney damage from SCD. These findings were shown during yesterday evening’s Poster session. Throughout today’s sessions, several abstracts will look at medical utilizations in children through adulthood in several geographic areas. In tonight’s Poster session, from 6:00 to 8:00 p.m. in Hall B1-B2, Level 1, Building B of the Georgia World Congress Center, Benjamin Ansa, MD, will present abstract 3181 in which he analyzed Medicaid data in 14 states, covering the mid-Atlantic to southeast. About half of the 20,000 patients were under the age of 20, and as age increased, the number of individuals decreased (especially in men), in- »»SCD Page A-5 Dr. Alan K. Burnett presents the Thomas H. Ham-Louis R. Wasserman Lecture. Accepting the Ever-Increasing Challenges of Aggressive Lymphomas BY MICHAEL R. BISHOP, MD other end goes, “Hey Mike, how are you doing? I have this really tough case of diffuse large cell that I’d like your thoughts on.” I listen intently, and think to myself, “Wow, where do these cases come from?” Then, it makes me think of a quote from George Patton. “Accept the challenges so that you may feel the exhilaration of victory.” New victories over aggressive lymphomas are becoming more difficult. Over the past 10 to 15 years, we have witnessed significant advancements in our understanding of the biology and improvements in clinical approaches T he phone rings. I quickly answer, “Hello, this is Dr. Bishop,” and the doctor on the for patients with diffuse large B-cell lymphoma (DLBCL). The incorporation of rituximab into standard front-line treatment, the widespread acceptance of the International Prognostic Index (IPI) score, and the introduction of geneexpression profiling have resulted in improved outcomes and a more refined, biologically based identification of favorable and unfavorable subgroups. However, these major advancements have also resulted in relatively incremental improvements in outcomes with ongoing research efforts and identification of several new clinical questions for which there are currently no clear answers. It was within the context of the ever-increasing differentiation of DLBCL patients that Craig Moskowitz, MD, from Memorial Sloan-Kettering Cancer Center, carefully planned yesterday’s session, “Non-Hodgkin Lymphoma I: Changing Therapeutic Strategies in Aggressive Lymphomas,” which was presented twice as part of the Education Program. The session was developed from the perspective of the challenges that consulting physicians repeatedly confront with this specific patient population. According to Dr. Moskowitz, “The three topics were chosen because I believe they are the most common consults a lymphoma expert sees in 2012-2013.” Specifically, Dr. Moskowitz focused on the following questions: 1) How do we best use modern prognostic factors to guide therapy, and how do we »»LYMPHOMAS Page A-4 http://www.hematology.org/ashnewsdaily2012_sunday

Table of Contents for the Digital Edition of ASH News Daily 2012 - Sunday, December 9, 2012

ASH News Daily 2012 - Sunday, December 9, 2012

http://www.nxtbookMEDIA.com